Naureen Quibria
Stock Analyst at Capital One
(n/a)
# 4,678
Out of 5,182 analysts
8
Total ratings
11.11%
Success rate
-44.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Naureen Quibria
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMEA Biomea Fusion | Initiates: Overweight | $25 | $1.54 | +1,523.38% | 1 | Aug 29, 2024 | |
| IMMP Immutep | Initiates: Overweight | $10 | $0.36 | +2,666.25% | 1 | May 17, 2024 | |
| ERAS Erasca | Initiates: Overweight | $8 | $17.81 | -55.08% | 1 | Mar 11, 2024 | |
| IMCR Immunocore Holdings | Initiates: Overweight | $84 | $30.83 | +172.46% | 1 | Aug 16, 2023 | |
| DAWN Day One Biopharmaceuticals | Initiates: Overweight | $40 | $21.45 | +86.48% | 1 | Feb 8, 2023 | |
| FENC Fennec Pharmaceuticals | Initiates: Overweight | $11 | $6.42 | +71.34% | 1 | Sep 7, 2022 | |
| GNTA Genenta Science | Initiates: Buy | $21 | $0.71 | +2,857.75% | 1 | Jan 13, 2022 | |
| KZIA Kazia Therapeutics | Initiates: Buy | $900 | $7.34 | +12,161.58% | 1 | Oct 14, 2021 |
Biomea Fusion
Aug 29, 2024
Initiates: Overweight
Price Target: $25
Current: $1.54
Upside: +1,523.38%
Immutep
May 17, 2024
Initiates: Overweight
Price Target: $10
Current: $0.36
Upside: +2,666.25%
Erasca
Mar 11, 2024
Initiates: Overweight
Price Target: $8
Current: $17.81
Upside: -55.08%
Immunocore Holdings
Aug 16, 2023
Initiates: Overweight
Price Target: $84
Current: $30.83
Upside: +172.46%
Day One Biopharmaceuticals
Feb 8, 2023
Initiates: Overweight
Price Target: $40
Current: $21.45
Upside: +86.48%
Fennec Pharmaceuticals
Sep 7, 2022
Initiates: Overweight
Price Target: $11
Current: $6.42
Upside: +71.34%
Genenta Science
Jan 13, 2022
Initiates: Buy
Price Target: $21
Current: $0.71
Upside: +2,857.75%
Kazia Therapeutics
Oct 14, 2021
Initiates: Buy
Price Target: $900
Current: $7.34
Upside: +12,161.58%